Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Exclusion Criteria

• •1. lymph node metastasis;
• •2. The tumor surrounds the renal artery;
• •3. Renal vein cancer thrombus;
• •4. Diffuse tumor growth, with no clear boundary from normal renal parenchyma;
• •5. General poor condition, anesthesia assessment cannot tolerate general anesthesia surgery;
• •6. Have serious cardiovascular and cerebrovascular diseases, uncontrollable hypertension and diabetes;
• •7. Patients who have long-term use of immunosuppressants after organ transplantation;
• •8. Patients who are currently using immunosuppressive drugs;
• •9. Patients with clear infection or fever;
• •10. Patients with T-cell lymphoma and myeloma;
• •11. Patients who have concurrent malignant tumors, are currently undergoing treatment for other benign or malignant tumors, or have a history of other malignant tumors within the past six months;
• •12. Metastatic renal cell carcinoma.
• •13. Received Chinese herbal medicine or immunomodulatory drugs with anti-tumor indications within 14 days prior to the first use of the investigational drug;
• •14. Perform systematic treatment (including thymosin, interferon, interleukin, except for local use to control pleural effusion).
• •15. Suffering from active or potentially recurrent autoimmune diseases, except for vitiligo, hair loss, psoriasis, or eczema that do not require systemic treatment; Hypothyroidism caused by autoimmune thyroiditis only requires stable doses of hormone replacement therapy; Type I diabetes requiring only a stable dose of insulin replacement therapy.
• •16. Simultaneously enrolled in another clinical study, unless it is an observational, non interventional clinical study or a follow-up period of an interventional study.
• •17. Known history of mental illness, drug abuse, alcoholism, or drug use.
• •18. Pregnant or lactating women.
• •19. Any past or current illness, treatment, or laboratory test abnormalities may confuse the research results, affect the full participation of the subjects in the study, or participation in the study may not be in the best interests of the subjects.